Company Description

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company.

The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.

Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Cadrenal Therapeutics, Inc.

Country	United States
Founded	2022
IPO Date	Jan 20, 2023
Industry	Biotechnology
Sector	Healthcare
Employees	4
CEO	Quang Pham

Contact Details

Address: 822 A1A North, Suite 306 Ponte Vedra, Florida 32082 United States
Phone	904 300 0701
Website	cadrenal.com

Stock Details

Ticker Symbol	CVKD
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$5.00
CIK Code	0001937993
ISIN Number	US1276361086
Employer ID	88-0860746
SIC Code	2834

Key Executives

Name	Position
Quang X. Pham	Chairman and Chief Executive Officer
Jeffrey Cole	Chief Operating Officer
Dr. James J. Ferguson FACC, M.D.	Chief Medical Officer

Latest SEC Filings

Date	Type	Title
Feb 12, 2025	SCHEDULE 13G/A	Filing
Feb 7, 2025	8-K	Current Report
Feb 3, 2025	S-8	Securities to be offered to employees in employee benefit plans
Jan 29, 2025	SCHEDULE 13D	Filing
Jan 15, 2025	SCHEDULE 13G/A	Filing
Dec 23, 2024	S-8	Securities to be offered to employees in employee benefit plans
Dec 20, 2024	424B5	Filing
Nov 25, 2024	424B3	Prospectus
Nov 22, 2024	EFFECT	Notice of Effectiveness
Nov 20, 2024	UPLOAD	Filing

View All SEC Filings